Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PURVI K SHAH

Allopathic & Osteopathic Physicians Internal Medicine Hospice and Palliative Medicine

NPI
1275580722
CMS profile
12118
Location
RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,410.74

108 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,179.56 104
Education $231.18 4

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PURVI K SHAH

NPI 1275580722 · CMS profile ID 12118

Allopathic & Osteopathic Physicians / Internal Medicine / Hospice and Palliative Medicine

RICHMOND, VA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275580722?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PURVI K SHAH, NPI 1275580722, CMS profile ID 12118. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275580722?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). PURVI K SHAH, NPI 1275580722, CMS profile ID 12118. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275580722?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
PURVI K SHAH, NPI 1275580722, CMS profile ID 12118, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 108 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1275580722?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

108 matching records · $2,410.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 108 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 108.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $22.0107/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133793471 CMS
Incyte Corporation $24.7707/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141240147 CMS
Novartis Pharmaceuticals Corporation $24.8207/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087305775 CMS
PFIZER INC. $13.4607/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131750400 CMS
Ipsen Biopharmaceuticals, Inc $23.9107/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091958211 CMS
PFIZER INC. $29.6207/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131698783 CMS
Incyte Corporation $17.4507/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141301093 CMS
Merck Sharp & Dohme LLC $15.0507/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141885979 CMS
Novartis Pharmaceuticals Corporation $13.2306/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087305773 CMS
Novartis Pharmaceuticals Corporation $1.3406/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087305767 CMS
Novartis Pharmaceuticals Corporation $23.9606/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087305769 CMS
Novartis Pharmaceuticals Corporation $2.9306/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087305771 CMS
E.R. Squibb & Sons, L.L.C. $13.4706/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101654231 CMS
Pharmacosmos Therapeutics Inc. $19.9306/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154826005 CMS
AstraZeneca Pharmaceuticals LP $34.5906/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104482926 CMS
PFIZER INC. $19.2006/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131698780 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.5306/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117944175 CMS
Novartis Pharmaceuticals Corporation $27.7506/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087305763 CMS
PUMA BIOTECHNOLOGY, INC. $25.0005/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113837564 CMS
Novartis Pharmaceuticals Corporation $20.8005/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087305777 CMS
PFIZER INC. $7.6205/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131315205 CMS
PFIZER INC. $13.7805/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131506437 CMS
Genentech USA, Inc. $33.1305/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133090949 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.2004/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144967113 CMS
ABBVIE INC. $17.3804/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106066108 CMS
Ipsen Biopharmaceuticals, Inc $22.7304/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091958207 CMS
Janssen Biotech, Inc. $16.1304/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078809785 CMS
Novartis Pharmaceuticals Corporation $16.9204/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087305753 CMS
Novartis Pharmaceuticals Corporation $6.7504/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087305755 CMS
Astellas Pharma US Inc $96.0004/04/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139346270 CMS
Astellas Pharma US Inc $99.0004/04/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139346278 CMS
Merck Sharp & Dohme LLC $19.6104/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141742905 CMS
Merck Sharp & Dohme LLC $22.6403/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141742747 CMS
Genmab U.S., Inc. $20.7603/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126830842 CMS
Novartis Pharmaceuticals Corporation $22.8603/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087305757 CMS
PFIZER INC. $20.0603/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131294296 CMS
Ipsen Biopharmaceuticals, Inc $22.7303/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091958203 CMS
Astellas Pharma US Inc $14.6203/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139269474 CMS
TerSera Therapeutics LLC $33.1503/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144717645 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.7803/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086203815 CMS
Genentech USA, Inc. $31.5703/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133090957 CMS
ABBVIE INC. $20.0002/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106066106 CMS
E.R. Squibb & Sons, L.L.C. $24.2002/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101654127 CMS
Janssen Biotech, Inc. $18.6202/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078811547 CMS
Eisai Inc. $24.7802/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110773847 CMS
Merck Sharp & Dohme LLC $18.0902/12/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141699324 CMS
Merck Sharp & Dohme LLC $17.5902/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141742903 CMS
AstraZeneca Pharmaceuticals LP $19.3502/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104535125 CMS
SOBI, INC $21.3702/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141416236 CMS
Merck Sharp & Dohme LLC $23.2202/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141935759 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $204.28 8
PY2021 $50.87 3
PY2022 $730.96 33
PY2023 $3,137.17 80
PY2024 $2,410.74 108
PY2025 $2,191.29 94

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $109,477.03 29
PY2024 Principal investigator $274,437.96 29
PY2023 Principal investigator $364,244.57 16
PY2022 Principal investigator $235,472.08 10
PY2021 Principal investigator $107,249.72 4
PY2020 Principal investigator $7,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $24,575.12 12/31/2025 Non-covered Recipient Entity
Virginia Cancer Institute
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Th No dispute reported 06/30/2026 1232928191
Principal investigator 1 Merck Sharp & Dohme LLC $10,481.94 12/31/2025 Non-covered Recipient Entity
Virginia Cancer Institute
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Th No dispute reported 06/30/2026 1232928193
Principal investigator 1 Merck Sharp & Dohme LLC $18,793.71 12/31/2025 Non-covered Recipient Entity
Virginia Cancer Institute
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B No dispute reported 06/30/2026 1232928461
Principal investigator 1 GlaxoSmithKline, LLC. $2,740.72 08/14/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192173011
Principal investigator 1 GlaxoSmithKline, LLC. $150.00 07/23/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192172999
Principal investigator 1 GlaxoSmithKline, LLC. $75.00 07/23/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192173024
Principal investigator 1 GlaxoSmithKline, LLC. $375.00 07/23/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192173029
Principal investigator 1 GlaxoSmithKline, LLC. $75.00 07/23/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192175840
Principal investigator 1 GlaxoSmithKline, LLC. $75.00 07/23/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192175843
Principal investigator 1 GlaxoSmithKline, LLC. $225.00 07/23/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192175846
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 07/23/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192175860
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 07/23/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192175868
Principal investigator 1 GlaxoSmithKline, LLC. $350.00 06/25/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192176735
Principal investigator 1 GlaxoSmithKline, LLC. $2,200.00 06/20/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192173003
Principal investigator 1 GlaxoSmithKline, LLC. $900.00 06/09/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192175864
Principal investigator 1 GlaxoSmithKline, LLC. $900.00 06/09/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192176745
Principal investigator 1 GlaxoSmithKline, LLC. $1,894.23 05/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192173015
Principal investigator 1 Mirati Therapeutics, Inc. $11,146.26 05/08/2025 Non-covered Recipient Entity
Oncare Alliance, Llc
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236530812
Principal investigator 1 GlaxoSmithKline, LLC. $3,041.41 04/09/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192175856
Principal investigator 1 Merck Sharp & Dohme LLC $16,009.60 03/10/2025 Non-covered Recipient Entity
Virginia Cancer Institute
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Th No dispute reported 06/30/2026 1232928189
Principal investigator 1 Merck Sharp & Dohme LLC $4,000.00 03/10/2025 Non-covered Recipient Entity
Virginia Cancer Institute
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B No dispute reported 06/30/2026 1232928419
Principal investigator 1 GlaxoSmithKline, LLC. $3,029.72 02/24/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192172996
Principal investigator 1 GlaxoSmithKline, LLC. $1,100.00 01/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192117721
Principal investigator 1 GlaxoSmithKline, LLC. $550.00 01/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192173008
Principal investigator 1 GlaxoSmithKline, LLC. $1,100.00 01/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192173020
Principal investigator 1 GlaxoSmithKline, LLC. $550.00 01/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192175835
Principal investigator 1 GlaxoSmithKline, LLC. $550.00 01/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192175850
Principal investigator 1 GlaxoSmithKline, LLC. $2,889.32 01/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192176739
Principal investigator 1 GlaxoSmithKline, LLC. $1,100.00 01/28/2025 Non-covered Recipient Entity
EXIGENT RESEARCH
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192176749